Josep Roma

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1289362/publications.pdf

Version: 2024-02-01

23	691	567247 15	677123 22
papers	citations	h-index	g-index

23	23	23	1523
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo. Blood, 2001, 97, 1703-1711.	1.4	114
2	uPA deficiency exacerbates muscular dystrophy in MDX mice. Journal of Cell Biology, 2007, 178, 1039-1051.	5.2	66
3	BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene, 2016, 35, 5179-5190.	5.9	65
4	microRNAs as pharmacological targets in cancer. Pharmacological Research, 2013, 75, 3-14.	7.1	56
5	Notch Pathway Inhibition Significantly Reduces Rhabdomyosarcoma Invasiveness and Mobility In Vitro. Clinical Cancer Research, 2011, 17, 505-513.	7.0	49
6	Clonal dynamics in osteosarcoma defined by RGB marking. Nature Communications, 2018, 9, 3994.	12.8	40
7	Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay. Journal of Cancer Research and Clinical Oncology, 2006, 132, 356-362.	2.5	36
8	Notch, Wnt,andHedgehogPathways in Rhabdomyosarcoma: From Single Pathways to an Integrated Network. Sarcoma, 2012, 2012, 1-7.	1.3	34
9	MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. Oncotarget, 2016, 7, 9271-9287.	1.8	31
10	Longitudinal pathologic study of the gastrocnemius muscle group in mdx mice. Acta Neuropathologica, 2004, 107, 27-34.	7.7	29
11	DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. Cancer Letters, 2017, 386, 196-207.	7.2	25
12	Evolution of pathological changes in the gastrocnemius of the mdx mice correlate with utrophin and ?-dystroglycan expression. Acta Neuropathologica, 2004, 108, 443-452.	7.7	23
13	Notch-mediated induction of N-cadherin and Î±9-integrin confers higher invasive phenotype on rhabdomyosarcoma cells. British Journal of Cancer, 2012, 107, 1374-1383.	6.4	23
14	Origins of DNA methylation defects in Wilms tumors. Cancer Letters, 2019, 457, 119-128.	7.2	23
15	Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance. Cell Death and Disease, 2020, 11, 634.	6.3	17
16	Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments. Clinical and Translational Oncology, 2017, 19, 44-50.	2.4	15
17	Engineering pHâ€Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics. Small, 2022, 18, e2101959.	10.0	13
18	Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma. Stem Cells International, 2017, 2017, 1-14.	2.5	10

#	Article	IF	Citations
19	CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. Cancers, 2020, 12, 1922.	3.7	7
20	The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis. Cell Death and Disease, 2020, 11, 773.	6.3	7
21	Optimization of rhabdomyosarcoma disseminated disease assessment by flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 1020-1029.	1.5	4
22	MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment. Cell Death Discovery, 2022, 8, 172.	4.7	4
23	DAX-1 Expression in Pediatric Rhabdomyosarcomas: Another Immunohistochemical Marker Useful in the Diagnosis of Translocation Positive Alveolar Rhabdomyosarcoma. PLoS ONE, 2015, 10, e0133019.	2.5	0